Difference between revisions of "High altitude pulmonary edema"
(→Evaluation) |
(→Evaluation) |
||
Line 50: | Line 50: | ||
*Clinical diagnosis | *Clinical diagnosis | ||
+ | ===Expected SpO<sub>2</sub> and PaO<sub>2</sub> levels at altitude=== | ||
{| class="wikitable" style="float:right; margin:0 1em;" | {| class="wikitable" style="float:right; margin:0 1em;" | ||
− | |||
|- | |- | ||
!Altitude | !Altitude |
Revision as of 19:14, 2 March 2020
Contents
Background
- Also known as HAPE
- Noncardiogenic pulmonary edema due to increased microvascular pressure in the pulmonary circulation
- Hypoxic pulmonary vasoconstriction leads to pulmonary hypertension
- Most lethal of the altitude illnesses
- Occurs in <1/10,000 skiers in Colorado; 2-3% of Mt. McKinley climbers
- Typical patient is strong and fit; may not have symptoms of altered mental status before onset of HAPE
- Most commonly noticed on the second night at a new altitude
Risk Factors
- Heavy exertion
- Rapid ascent
- Cold
- Excessive salt ingestion
- Use of a sleeping medication
- Preexisting pulmonary hypertension
- Preexisting respiratory infection (children)
- Previous history of HAPE
Clinical Features
- Early
- Late
- Dyspnea at rest, marked weakness, productive cough, cyanosis, generalized rales
- Cough generates pink, frothy sputum
- Tachycardia and tachypnea correlate with severity of illness
- Altered mental status and coma (from severe hypoxemia)
Differential Diagnosis
High Altitude Illnesses
- Acute mountain sickness
- Chronic mountain sickness
- High altitude cerebral edema
- High altitude pulmonary edema
- High altitude peripheral edema
- High altitude retinopathy
- High altitude pharyngitis and bronchitis
- Ultraviolet keratitis
Pulmonary Edema Types
Cardiogenic pulmonary edema
Noncardiogenic pulmonary edema
- Negative pressure pulmonary edema
- Upper airway obstruction
- Reexpansion pulmonary edema
- Strangulation
- Neurogenic causes
- Iatrogenic fluid overload
- Multiple blood transfusions
- IV fluid
- Inhalation injury
- Pulmonary contusion
- Aspiration pneumonia and pneumonitis
- Other
- High altitude pulmonary edema
- Hypertensive emergency
- ARDS
- Sympathetic crashing acute pulmonary edema (SCAPE)
- Immersion pulmonary edema
- Hantavirus pulmonary syndrome
- Missed dialysis in kidney failure
- Naloxone reversal
Evaluation
Workup
- ECG - right strain pattern
- CXR - Progresses from interstitial → localized-alveolar → generalized-alveolar infiltrates
- ABG - Hypoxemia with respiratory alkalosis
Evaluation
- Clinical diagnosis
Expected SpO2 and PaO2 levels at altitude
Altitude | SpO2 | PaO2 (mm Hg) |
---|---|---|
1,500 to 3,500 m (4,900 to 11,500 ft) | about 90% | 55-75 |
3,500 to 5,500 m (11,500 to 18,000 ft) | 75-85% | 40-60 |
5,500 to 8,850 m (18,000 to 29,000 ft) | 58-75% | 28-40 |
Management
- Immediate descent is treatment of choice - minimize exertion
- If cannot descend use combination of:
- Supplemental O2 - An oxygen concentrator is often used at high altitude ski resorts after the patient is titrated down to nasal cannula. A portable oxygen tank is used for ambulation. Can completely resolve the pulmonary edema within 36-72hr
- Hyperbaric bag - (e.g. Gamow Bag). Should not delay descent, if possible.
- Keep patient warm (cold stress elevates pulmonary artery pressure)
- Use expiratory positive airway pressure mask
- Nifedipine 30mg ER q12hr (or 20mg normal-release q8hr)[1]
- May consider the other medications listed below that are usually used for prevention
Disposition
- Admission
- Warranted for severe illness that does not respond immediately to descent
- Discharge
- Progressive clinical and X-ray improvement and a PaO2 of 60mmHg or SaO2>90%
- May re-ascend in 2-3 days if mild-moderate symptoms resolved that only required descent as the intervention
Prevention
- Nifedipine 20mg q8hr or 30mg ER q12hr while ascending is effective prophylaxis in patients with prior episodes of HAPE
- Tadalafil 10mg BID 24hr prior to ascent OR Sildenafil 50mg q8hr
- Salmeterol 125 mcg inhaled BID
- Acetazolamide 125mg BID for prevention of hypoxia
See Also
References
- ↑ Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2014 Update. Wilderness & Environmental Medicine. 2014(25): S4–S14)